⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2095161 | 0.73 | — | — | |
| SCHEMBL7673055 | 0.69 | — | — | |
| SCHEMBL9500220 | 0.66 | — | — | |
| SCHEMBL3364417 | 0.63 | — | — | |
| SCHEMBL570696 | 0.62 | — | — | |
| SCHEMBL2095164 | 0.61 | — | — | |
| SCHEMBL2021913 | 0.60 | ALDH1A1 (0.36) | — | |
| SCHEMBL1356861 | 0.60 | — | — | |
| SCHEMBL8668941 | 0.58 | — | — | |
| SCHEMBL7075903 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9546173-B2 | Substituted pyrrolo[3,4-d]pyrimidines as kinase inhibitors | NOVARTIS AG (CH) | 2017-01-17 | — | — | US | disclosed |
| EP-2897961-B1 | DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-10-26 | — | — | EP | disclosed |
| US-20150274733-A1 | DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-10-01 | — | — | US | disclosed |
| EP-2897961-A1 | DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS | Novartis AG (CH) | 2015-07-29 | — | — | EP | disclosed |
| WO-2014047020-A1 | DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-03-27 | — | — | WO | disclosed |
| US-6596726-B1 | Method of inhibiting epidermal growth factor by treating, with an effective inhibiting amount, a mammal, in need thereof inhibit the epidermal growth factor receptor and related receptors and, in particular, their tyrosine kinase enzyme | WARNER LAMBERT COMPANY | 2003-07-22 | — | — | US | disclosed |
| US-5679683-A | USEFUL FOR TREATING CANCER, ARTHRITIS, PSORIASIS, VASCULAR RESTENOSIS AND ANGIOGENESIS | WARNER-LAMBERT COMPANY (US) | 1997-10-21 | — | — | US | disclosed |
| EP-0741711-A1 | TRICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1996-11-13 | — | — | EP | disclosed |
| WO-1995019970-A1 | TRICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1995-07-27 | — | — | WO | disclosed |